What specific cardiology recommendation or management is needed for a patient?

Management of Chronic Coronary Syndromes: Comprehensive Cardiology Recommendations

All patients with chronic coronary syndromes require comprehensive risk factor management including statins, blood pressure control to 120-130 mmHg (130-140 mmHg if >65 years), and treatment of diabetes, with myocardial revascularization indicated when angina persists despite optimal antianginal therapy. 1

Core Medical Therapy

Lipid Management

• Statins are mandatory for all CCS patients to reduce morbidity and mortality 1
• If LDL goals are not achieved with maximum tolerated statin dose, add ezetimibe 1
• For very high-risk patients not at goal despite statin plus ezetimibe, add a PCSK9 inhibitor 1

Blood Pressure Control

• Target systolic BP 120-130 mmHg in general population 1
• Target systolic BP 130-140 mmHg in patients >65 years 1
• In hypertensive patients with recent MI, use beta-blockers AND RAS blockers (ACE inhibitors or ARBs) 1
• In symptomatic angina, use beta-blockers and/or calcium channel blockers 1
• Never combine ACE inhibitors with ARBs - this is contraindicated 1

ACE Inhibitors/ARBs

• ACE inhibitors (or ARBs if intolerant) are indicated in presence of heart failure, hypertension, or diabetes 1
• Specifically recommended in CCS patients with diabetes for event prevention 1

Diabetes Management in CCS

• Control BP, LDL-C, and HbA1c to target values 1
• SGLT2 inhibitors (empagliflozin, canagliflozin, or dapagliflozin) are recommended in patients with diabetes and CVD 1
• GLP-1 receptor agonists (liraglutide or semaglutide) are recommended in patients with diabetes and CVD 1
• Perform periodic resting ECG in asymptomatic diabetic patients to detect conduction abnormalities, atrial fibrillation, and silent MI 1

Antianginal Therapy

Symptomatic Patients

• Beta-blockers and/or calcium channel blockers for symptomatic angina 1
• Proceed to myocardial revascularization when angina persists despite antianginal drug treatment 1

Antithrombotic Management

Standard CCS

• Aspirin monotherapy is standard 1
• Add proton pump inhibitor in patients at high risk of gastrointestinal bleeding receiving aspirin monotherapy, DAPT, or OAC monotherapy 1

Post-PCI with Atrial Fibrillation

• Peri-procedural aspirin and clopidogrel are required for coronary stent implantation 1
• Use a NOAC (apixaban 5 mg BID, dabigatran 150 mg BID, edoxaban 60 mg daily, or rivaroxaban 20 mg daily) in preference to warfarin when combining with antiplatelet therapy 1
• Never use ticagrelor or prasugrel as part of triple antithrombotic therapy with aspirin and OAC 1

Atrial Fibrillation Management

• When initiating oral anticoagulation in AF patients eligible for NOAC, prefer NOAC over warfarin 1
• Long-term OAC (NOAC or warfarin with time in therapeutic range >70%) is required for CHA₂DS₂-VASc score >2 in males or >3 in females 1

Heart Failure with CCS

Rate Control in HF with Preserved Ejection Fraction

• Beta-blocker or nondihydropyridine calcium channel antagonist for resting heart rate control 1
• Combination of digoxin plus beta-blocker (or nondihydropyridine CCB in HFpEF) is reasonable for controlling resting and exercise heart rate 1

HF with Reduced Ejection Fraction

• Beta-blockers are essential - they relieve angina AND reduce morbidity and mortality 1
• ACE inhibitor therapy is mandatory in symptomatic HF or asymptomatic LV dysfunction post-MI to improve symptoms and reduce morbidity and mortality 1
• ARB as alternative if ACE inhibitor not tolerated, or angiotensin receptor-neprilysin inhibitor for persistent symptoms despite optimal therapy 1
• Add mineralocorticoid receptor antagonist (MRA) if symptomatic despite ACE inhibitor and beta-blocker to reduce morbidity and mortality 1
• Diuretics for symptomatic pulmonary or systemic congestion 1

Device Therapy in HF

• Implantable cardioverter-defibrillator (ICD) is indicated for documented ventricular dysrhythmia causing hemodynamic instability (secondary prevention) AND for symptomatic HF with LVEF <35% (primary prevention) to reduce sudden death and all-cause mortality 1
• Cardiac resynchronization therapy (CRT) is indicated for symptomatic HF patients in sinus rhythm with QRS ≥150 ms and LBBB morphology, with LVEF <35% despite optimal medical therapy 1
• CRT is also indicated for QRS 130-149 ms with LBBB and LVEF <35% 1
• In HF with bradycardia and high-degree AV block requiring pacing, use CRT with pacemaker rather than right ventricular pacing 1

Risk Stratification and Follow-up

Asymptomatic Patients

• Periodic cardiovascular healthcare visits to reassess risk status, lifestyle modifications, cardiovascular risk factor targets, and comorbidities 1
• In mild/no symptoms on medical treatment with high-risk non-invasive stratification, invasive coronary angiography (with FFR when necessary) is indicated if revascularization considered for prognosis improvement 1
• Coronary CTA is NOT recommended as routine follow-up for established CAD 1
• ICA is NOT recommended solely for risk stratification 1

Symptomatic Patients

• Risk stratification using stress imaging (preferred) or exercise stress ECG for new or worsening symptoms 1
• Expeditious referral for evaluation with significant symptom worsening 1
• ICA (with FFR/iwFR when necessary) for risk stratification in severe CAD, particularly if symptoms refractory to medical treatment or high-risk clinical profile 1
• Reassess CAD status in deteriorating LV systolic function without reversible cause (e.g., tachycardia, myocarditis) 1

Vasospastic Angina

• Obtain ECG during angina if possible 1
• Invasive angiography or coronary CTA is indicated in characteristic episodic resting angina with ST-segment changes resolving with nitrates/calcium antagonists to determine extent of underlying coronary disease 1
• First-line therapy: calcium channel blocker (e.g., verapamil 40 mg BID uptitrated) 1
• Second-line: add long-acting nitrate (e.g., isosorbide mononitrate 10 mg BID) 1

Special Populations

Valvular Heart Disease

• ICA is required before valve surgery if any of: history of CVD, suspected myocardial ischemia, LV systolic dysfunction, men >40 years, postmenopausal women, or ≥1 cardiovascular risk factor 1
• ICA indicated for evaluation of moderate-to-severe functional mitral regurgitation 1
• Do NOT routinely use stress testing in severe valvular disease to detect CAD due to low diagnostic yield and potential risks 1

Active Cancer

• Base treatment decisions on life expectancy, comorbidities (thrombocytopenia, thrombosis propensity), and drug interactions between CCS medications and antineoplastic agents 1
• If revascularization indicated in highly symptomatic patients with active cancer and increased frailty, use the least invasive procedure 1

Chronic Kidney Disease

• Control risk factors to target values 1
• Pay special attention to dose adjustments of renally excreted drugs 1
• Minimize iodinated contrast agents in severe CKD with preserved urine production to prevent further deterioration 1

Elderly Patients

• Pay particular attention to drug side effects, intolerance, and overdosing 1

Screening in Asymptomatic Subjects

• Use SCORE risk estimation system for asymptomatic adults >40 years without CVD, diabetes, CKD, or familial hypercholesterolemia 1
• Assess family history of premature CVD (fatal/non-fatal CVD event or established CVD diagnosis in first-degree male relatives <55 years or female relatives <65 years) 1
• Screen individuals <50 years with family history of premature CVD in first-degree relative for familial hypercholesterolemia using validated clinical score 1
• Carotid ultrasound IMT is NOT recommended for cardiovascular risk assessment 1
• Coronary CTA or functional imaging is NOT indicated in low-risk non-diabetic asymptomatic adults 1
• Routine circulating biomarkers are NOT recommended for cardiovascular risk stratification 1

Critical Pitfalls to Avoid

• Never combine ACE inhibitors with ARBs 1
• Never use ticagrelor or prasugrel in triple antithrombotic therapy 1
• Never give IV nondihydropyridine calcium channel antagonists, IV beta-blockers, or dronedarone in decompensated heart failure 1
• Never perform AV node ablation without pharmacological trial to control ventricular rate 1
• Never use coronary CTA as routine follow-up in established CAD 1
• Never perform ICA solely for risk stratification 1